About the NHS Screening Programmes

NHS Screening Programmes identify apparently health people who may be at increased risk or a disease or condition, enabling earlier treatment and better informed decisions. They are implemented on the advice of the UK National Screening Committee (UK NSC), which oversees screening policy in all four nations, and works with the different implementation bodies to support delivery.

Public Health England (PHE) is responsible for the NHS Screening Programmes. PHE is an executive agency of the Department of Health and works to protect and improve the nation’s health and wellbeing, and reduce health inequalities.

NHS Screening Programmes
Floor 2, Zone B
Skipton House
80 London Road
London SE1 6LH
Tel: 020 368 20890
www.screening.nhs.uk
Twitter: @PHE_Screening
© Crown copyright 2015

Image sources: PHE photo library

You may re-use this information (excluding logos) free of charge in any format or medium, under the terms of the Open Government Licence v.3.0. To view this licence, visit OGL or email psi@nationalarchives.gsi.gov.uk. Where third party material has been identified, permission from the respective copyright holder must be sought. Any enquiries regarding this publication should be sent to phe.screeninghelpdesk@nhs.net.

You can download this publication from www.screening.nhs.uk

Gateway ref: 2015002

Contents

1 Introduction

1.1 Conventions

1.2 Related documents

2 The Fetal Anomaly Screening Programme (FASP)

2.1 General principles of screening

2.2 Background

2.3 The policy

3 Screening tests

3.1 First trimester combined test

3.2 Second trimester quadruple test

3.3 National standards

4 Markers used in screening tests

4.1 Maternal age

4.2 Biochemical markers

4.3 Ultrasound markers

5 Screening risk

5.1 Risk cut-off

5.2 Risk calculation software

6 Role of the Screening Support Sonographer

6.1 Functions

7 Criteria for measuring NT and CRL

8 Departmental review of images

8.1 Rationale

8.2 Local quality assurance

8.3 Supplementary audit activities

8.4 The scoring process for departmental review of images

9 DQASS

9.1 Aims of DQASS

9.2 Information DQASS needs from laboratories

9.3 DQASS reports

Withdrawn 17 August 2021
The purpose of this handbook is to bring together in one publication the Fetal Anomaly Screening Programme’s (FASP) guidelines and recommendations that relate to the screening pathway and are not covered in detail in the other handbooks.

1.1 Conventions
Throughout the document the following are used interchangeably:
- Down’s syndrome is referred to as T21
- Edwards’ syndrome as T18
- Patau’s syndrome as T13

1.2 Related documents

a. Handbook for laboratories
This sets out the requirements for laboratory staff involved in the pathways for first trimester screening for Down’s, Edwards’ and Patau’s syndromes and second trimester biochemical screening for Down’s syndrome.

fetalanomaly.screening.nhs.uk/publications

c. Department of Health / NHS England Service – Specification for Screening for Down’s, Edwards’ and Patau’s syndromes (No. 16) and Specification for 18+0 to 20+6 fetal anomaly scan (No.17)
These outline the service and quality indicators expected by NHS England for the population for whom it is responsible and which meets the policies, recommendations and standards of the UK National Screening Committee (UK NSC). It is relevant for both commissioners and providers of the screening service to enable an understanding of the care pathway pregnant women should expect and how that service should be delivered. Both documents should be read in full to gain a better understanding of the expected roles and responsibilities for the various healthcare professionals involved in providing the screening pathway. These are updated annually and new versions posted to the website.

fetalanomaly.screening.nhs.uk/specification

d. Standards
These define a set of standards relating to screening for Down’s, Edwards’ and Patau’s syndromes and the 18th to 20th week fetal anomaly scan.

fetalanomaly.screening.nhs.uk
2 The Fetal Anomaly Screening Programme (FASP)

2.1 General principles of screening
Screening is a process of identifying apparently healthy people who may be at increased risk of a disease or condition. They can then be offered information, further tests and appropriate treatment to reduce their risk and/or any complications arising from the disease or condition.

Further information regarding the general principles of screening can be found at: www.screening.nhs.uk

2.2 Background
NHS FASP, based in Public Health England, is an expert team that ensures national consistency and provides expertise. They support and manage on-going roll out, technical and professional development of the programme and ensure quality and safety standards are maintained and continuously improved.

The screening programme has evolved from its establishment in 2001 when the majority of screening was performed using maternal biochemistry in the second trimester. The recommended method of screening is now first trimester screening, combining maternal age, biochemistry and ultrasound measurement of fetal nuchal translucency to provide a pregnant woman with the risk of having a baby with Down’s, or Edwards’/Patau’s syndromes. The offer of a fetal anomaly scan is recommended and where accepted should be undertaken between 18+0 to 20+6 weeks of pregnancy. The first scan usually takes place between 10 to 14 weeks and includes a blood sample taken to test for Down’s, Edwards’/Patau’s syndromes, with a second scan for fetal anomalies between 18th to 20th weeks. The timing of the scans allows for further diagnostic tests if required and ensures women have time to consider decisions about continuing their pregnancy.

The second scan is designed to identify abnormalities which indicate the baby may die shortly after birth, conditions that may benefit from treatment before birth, to plan delivery in an appropriate hospital/centre and/or to optimise treatment after the baby is born. Some women may choose not to be screened at all, or only for some conditions and it is important that this choice is respected.

FASP has established standardisation of the following to enable commissioners and quality assurance teams to assess the quality of the service provided. These include:
- national standards, guidance and risk cut-off for Down’s, Edwards’ and Patau’s syndromes screening programme in the light of emerging evidence
- a statistical service to ensure that laboratories have access to the best advice in maintaining their population medians
- specifications for risk calculation software to make sure that all laboratories calculate risks in a uniform way
- use of a base menu and fetal cardiac protocol to enable consistency in the structures examined as part of the 18th to 20th week fetal anomaly scan

2.3 The policy
FASP offers screening to all eligible pregnant women in England to assess the risk of the baby being born with Down’s, or Edwards’/Patau’s syndromes or a number of fetal anomalies (structural abnormalities of the developing fetus).

FASP aims to ensure there is equal access to uniform and quality-assured screening across England and women are provided with high quality information so they can make an informed choice about their screening and pregnancy options. Education and training resources are available for staff covering all stages of the process, from informing women of test availability, through to understanding and supporting their decisions.

The screening policy is to offer screening to assess the risk of the baby being born with Down’s or Edwards/Patau’s syndromes. The test of choice for both singleton and twin pregnancies is first trimester combined screening. Women can choose:
- not to have screening
- to have screening for T21 and T18 / T13
- to have screening for T21 only
- to have screening for T18 / T13 only

Withdrawn 17 August 2021
3 Screening tests

3.1 First trimester combined test
The combined test uses maternal age, the nuchal translucency measurement (NT) and two biochemical tests, free beta hCG and PAPP-A, together with the gestational age calculated from the crown rump length (CRL) measurement, to calculate the risk of the pregnancy being affected by T21 or T18/T13. The optimal time to perform the combined test is between 11+2 weeks to 14+1 weeks of gestation, which corresponds to a CRL of 45.0 mm to 84.0 mm. If the ultrasound measurement shows that the CRL is less than 45.0 mm, the woman should be recalled for a further scan to measure the NT. If the CRL is greater than 84.0 mm, the second trimester quadruple test should be offered.

The first trimester combined test allows earlier decision making for parents. In practice, two models are available for performing the combined test:

A maternal blood specimen may be taken (from 10 weeks onwards) prior to the ultrasound scan. The biochemistry results can then be made available at the time of the NT scan and the combined test result can be calculated at the time of the appointment. Although the result may be calculated by the sonographer, it is recommended that the laboratory take primary responsibility for the risk calculation software and audit all results.

A maternal blood specimen may be taken at the time of the ultrasound scan and the combined test result made available within a few days of the biochemistry results being authorised by the laboratory.

In cases where screening is accepted but it is not possible to obtain the NT measurement at the first appointment, at least one other attempt should be offered, this may be on the same day, or at a later date. If it is not possible to obtain an accurate NT measurement despite ‘twice on the couch’ then further attempts do not have to be offered and the woman should be referred into the second trimester screening pathway.

FASP recommends that the Down’s and/or Edwards/Patau’s screening risk generated from first trimester combined screening must not to be recalculated up or down following the initial screening test or at the 18+0 to 20+6 fetal anomaly ultrasound scan due to the presence or absence of a single ultrasound marker of less predictive power than increased nuchal fold (Smith-Bindman et al, 2001).

3.2 Second trimester quadruple test
The quadruple test uses maternal age and four biochemical markers measured from 14+2 weeks until 20+0 weeks - AFP, hCG (total, intact or free beta subunit), uE3 and Inhibin-A. Although this combination of markers has a lower detection and standardised screen positive rate than the combined test, it is the nationally recommended screening strategy for the second trimester. The optimum time for testing in the second trimester is around 16 weeks of gestation.

There will always be a need for a screening test in the second trimester for those women who book too late for first trimester testing or when an NT measurement cannot be obtained in the first trimester. An ultrasound scan will be required to date the pregnancy and fetal head circumference is the recommended measurement used for women presenting in the second trimester. Further information regarding the practicalities of combining dating and screening requirements at the early pregnancy scan are explored in more detail in the following article by Chudleigh et al (2011), a practical solution to combining dating and screening for Down’s syndrome.

3.3 National standards
The national standards seen in Table 1 state the threshold for the national programme and will be reported on each year by DQASS.

<table>
<thead>
<tr>
<th>Screening strategy</th>
<th>Acceptable Thresholds</th>
<th>Achievable Thresholds</th>
</tr>
</thead>
<tbody>
<tr>
<td>T21</td>
<td>Standardised DR 85%</td>
<td>Standardised SPR 1.9-2.4%</td>
</tr>
<tr>
<td>T18/T13</td>
<td>Standardised DR 80%</td>
<td>Standardised SPR 0.13-0.17%</td>
</tr>
<tr>
<td>T21/T18/T13</td>
<td>Standardised SPR 1.8-2.5%</td>
<td>Standardised SPR 1.9-2.4%</td>
</tr>
<tr>
<td>Quadruple (T21)</td>
<td>Standardised DR 80%</td>
<td>Standardised SPR 2.7-3.3%</td>
</tr>
</tbody>
</table>

*The DR and SPR for the quadruple test relate to singleton pregnancies only*
4 Markers used in screening tests

4.1 Maternal age

All women have a chance of having a baby with Down’s or Edwards'/Patau’s syndrome and this chance increases with age. Table 2 below shows that the older a mother, the more chance she has of having a baby with one of these conditions.

Table 2

<table>
<thead>
<tr>
<th>Maternal age</th>
<th>Chances of having a pregnancy affected by Down's syndrome</th>
<th>Probability</th>
</tr>
</thead>
<tbody>
<tr>
<td>20 years</td>
<td>1 in 1500</td>
<td>0.07%</td>
</tr>
<tr>
<td>30 years</td>
<td>1 in 900</td>
<td>0.1%</td>
</tr>
<tr>
<td>40 years</td>
<td>1 in 100</td>
<td>1%</td>
</tr>
</tbody>
</table>

Figure 1: Graph to illustrate the likelihood of a pregnancy affected by Down’s, Edwards’ or Patau’s syndromes according to maternal age showing T21 (black line), T18 (blue line), T13 (green line). Risks are at the time of the 12 weeks scan.

4.2 Biochemical markers

Information about biochemical markers can be found in the Handbook for Laboratories at: fetalanomaly.screening.nhs.uk/publications

Effect of vaginal bleeding on biochemical markers used in screening for Down’s, Edwards’ and Patau’s syndromes

There are concerns that a history of significant maternal vaginal bleeding might change the levels of biochemical markers used in the combined test. FASP recommends women are offered the combined test in the normal way (calculating the risk based on maternal age, NT, free beta hCG and PAPP-A levels), as current evidence suggests that the biochemical marker levels are not significantly different in women with this history.

Effect of ‘vanished twin’ on biochemical markers used in screening for Down’s, Edwards’ and Patau’s syndromes

When ultrasound shows there is an empty second pregnancy sac, the biochemical markers appear no different to those in a singleton pregnancy and the combined test of NT, PAPP-A and free beta hCG can be used to calculate the risk.

When ultrasound shows that there is a second pregnancy sac containing a non-viable fetus (sometimes called ‘vanished twin’), it is possible there could be a contribution to the maternal biochemical markers for many weeks. It is recommended that in this event services undertake the risk calculation based on the maternal age and nuchal translucency only (ie without biochemistry).

4.3 Ultrasound markers

Nuchal translucency (NT)

Nuchal translucency is the ultrasound appearance of a collection of fluid under the skin behind the neck of the fetus in the first trimester of pregnancy. The thickness of the nuchal translucency is measured by the sonographer and used in calculating the chance of the pregnancy being affected by Down’s and/or Edwards'/Patau’s syndromes. An increased NT measurement is associated with an increased chance of autosomal trisomies as well as other fetal anomalies such as cardiac defects but as with all screening tests, a pregnancy with an increased NT may also have a normal outcome.

Where screening in the first trimester using the combined screening strategy is accepted, the biochemical component of the test must be completed. Therefore, where an NT measurement of ≥3.5 mm is recorded, a blood sample must be taken but referral should not be delayed to await the biochemistry marker levels and results should be forwarded to the clinician as soon as they are available to support discussion of further investigative options with the woman.

Crown rump length (CRL)

The gestational age of the fetus is calculated from the ultrasound measurement between the top of the head (crown) to the bottom of the buttocks (rump) known as the crown rump length (CRL). The gestational age in days can be calculated by the use of tables or an equation from the CRL measurement. Whilst it is acknowledged that the description of the first trimester screening test is primarily described within a gestational age timeframe (10+0 weeks to 14+6 weeks), entry into the screening programme within the laboratory should be based on CRL measurements of 45.0mm to 84.0mm rather than gestational age of weeks and days. Because the concentration of the biochemistry markers is dependent on the gestational age of the fetus, it is important that the CRL is measured accurately.

Head circumference (HC)

If the CRL is greater than 84.0mm, it is recommended that the gestational age of the fetus is calculated using the fetal head circumference (HC). Ultrasound measurements of the biparietal diameter (BPD using ‘outer to outer’ calliper placement) and the occipital-frontal diameter (OFD using ‘outer to outer’ calliper placement) are used to calculate the head circumference which can then be used to date the pregnancy. Loughna et al (2009).

Information about NHS training for competency in the measurement of nuchal translucency (NT) and crown-rump length (CRL) and the recommend measurements charts can be found at: fetalanomaly.screening.nhs.uk/combinedscreeningresources
5 Screening risk

5.1 Risk cut-off
FASP defines the national cut off and this is currently set at 1 in 150 at term for both first and second trimester screening tests. A woman with a risk of 1 in 150, or greater (1 in 2 – 1 in 150), of having a pregnancy affected by Down’s or Edwards’/Patau’s in the first trimester or Down’s syndrome only in the second trimester is considered to be in the ‘higher risk’ group. Women in this group are offered diagnostic tests such as chorionic villus sampling or amniocentesis to directly investigate the fetal chromosomes. Women having screening using the combined test, dependant of their screening choice, up to two risks will be reported:
- a risk for T21 and a risk for T18/T13
- a risk for T21 only or T18/T13 only

The cut-off is based on a risk at term rather than a risk at the time of the screening test. The main reason for this is that the original studies on the likelihood of having a Down’s syndrome affected pregnancy is based on the birth prevalence of the condition before screening was implemented. There is a significant fetal loss rate between the time of screening and delivery but the loss rate is not exactly known. A risk at the time of screening would need to make assumptions about the fetal loss rate during the various stages of pregnancy. This will be kept under review.

5.2 Risk calculation software
The software used to calculate the Down’s, and Edwards’/Patau’s syndromes risk from the biochemical and ultrasound markers is complex and best provided and supported by commercial suppliers. The screening programme developed a specification for the risk calculation software to be supplied to the English laboratories and which is available at:

fetalanomaly.screening.nhs.uk/dqass

This specifies in detail all the aspects that need to be incorporated into the software package to provide consistent risk results across the country. Some variables that need to be entered into the software are defined by the local user to take account of the reagents used for screening and the characteristics of the local population they are screening. These would normally be decided by the laboratory in collaboration with Down’s syndrome screening Quality Assurance Support Service (DQASS) – the statistical support service provided by Public Health England (PHE).

6 Role of the Screening Support Sonographer

To achieve the national standards and to ensure a high quality test it is imperative that the ultrasound measurements are accurate. To assist the service in achieving these key aims, this handbook sets out the following:

6.1 Functions
The main functions of the SSS are:
- internal quality assurance – regular departmental review of images is an essential aspect of the role and will provide ongoing support to ensure improvements in practice can be achieved and maintained
- DQASS – liaise with the Down’s syndrome Screening Quality Assurance Support Service (DQASS) to facilitate a high quality local screening programme. DQASS also provides a statistical service in relation to screening for Edwards’ and Patau’s syndromes, however, the name will remain unchanged
- action plans – devise and implement supportive action plans where required. Monitor progress and resolution of these action plans
- communication – liaise with ultrasound practitioners, the Trust’s antenatal and newborn screening board, the screening laboratory, screening and immunisation lead and teams (Silts) and regional quality assurance team (RQAT)
- record keeping – maintains departmental records of training, support and both internal and external quality assurance
- training and support – involvement in the practical training and support of colleagues in relation to the measurement of NT and CRL
7 Criteria for measuring NT and CRL

Table 3 - Recommended criteria for measurement of NT for combined screening

<table>
<thead>
<tr>
<th>NT</th>
<th>Detail to be demonstrated</th>
</tr>
</thead>
</table>
| Midline section     | • Horizontal sagittal* section of the fetus extending from crown to upper aspect of the heart which may be supine or prone**  
                      • Head in line with the body with the NT visible along the length of the neck  
                      • Echogenic tip of the nose  
                      • Rectangular shape of the palate  
                      • Translucent diencephalon  
                      • Frontal process of the maxilla should not be visible |
| Position            | • Pocket of fluid, at least equivalent in size to the width of the palate, should be visible between the fetal chin and chest  
                      • Angle of the palate relative to the horizontal should be between 30° and 60°  
                      • Nasal tip should be level with, or above, the anterior chest wall |
| Magnification        | • The section should fill over 60% of the screen |
| Calliper placement  | • Callipers should be placed on the upper and lower edges of the NT  
                      • Widest part of the NT should be measured |
| Image archiving      | • The NT should be measured at least twice and the maximum measurement that meets the criteria should be recorded  
                      • The image demonstrating the measured NT which has been reported should be archived |

* In all criteria the term sagittal describes a midline longitudinal section  
** FASP does not recommend screening for nasal bone absence or hypoplasia, thus allowing measurement of the NT with the fetus in the prone position

Table 4 - Recommended criteria for measurement of CRL for pregnancy dating and combined screening (Loughna P et al (2009))

<table>
<thead>
<tr>
<th>CRL</th>
<th>Detail to be demonstrated</th>
</tr>
</thead>
</table>
| Midline section      | • Sagittal section of the fetus with the head in line with the full length of the body  
                      • Echogenic tip of the nose  
                      • Rectangular shape of the palate  
                      • Translucent diencephalon  
                      • CRL axis should be between 0° and 30° to the horizontal  
                      • Clearly defined crown and rump |
| Position             | • Pocket of fluid, at least equivalent in size to the width of the palate, should be visible between the fetal chin and chest  
                      • Fetal palate angle should be 30° to 60° relative to the horizontal  
                      • Nasal tip should be level or above the anterior abdominal wall |
| Magnification         | • Entire CRL section should fill over 60% of the screen |
| Calliper placement   | • Correct calliper placement on outer borders of crown and rump  
                      • Longest length of the fetus should be measured |
| Image archiving       | • The CRL should be measured at least twice and the maximum measurement that meets the criteria should be recorded  
                      • The image demonstrating the measured CRL which has been reported should be archived |

Withdrawn 17 August 2021
8 Departmental review of images

The role of the screening support sonographer (SSS) is to:
- perform quarterly departmental review of images
- record results as per local organisational policy
- feedback results of review to individual practitioners
- develop action plan for improvement if required
- prepare audit information for RQAT when required

8.1 Rationale
Departmental review of images is equally as important as the DQASS statistical analysis of an individual’s NT and CRL measurements.
Departmental review of images is not designed to be a performance management tool but provides local quality assurance.
The review process aims to encourage best practice and to assist and support ultrasound practitioners in making continuous improvements in their NT and CRL measurement technique and maintain best practice once achieved.
Taking part in three-monthly image review with the SSS and consulting the document entitled ‘A guide to getting the most from the ultrasound equipment when measuring Nuchal Translucency’ is strongly recommended.

8.2 Local quality assurance
- each practitioner must have three randomly selected paired images (NT and CRL) reviewed every three months
- each image should be subjectively scored using the FASP image guidance tool
- each practitioner should receive timely feedback from the SSS
- evidence may be sought by the RQAT that, as a minimum, all components of the departmental image review is audited

8.3 Supplementary audit activities
These are designed to support and encourage best practice (not mandatory and not audited).
- group review of a selection of images
- anonymised scored images shared within team
- each practitioner measures selected NT/CRL images previously stored on the ultrasound machine. Results are then compared and shared
- companion scanning – good for image optimisation, communication skills and time management
- sharing the overall departmental review with individual practitioners should also be considered

8.4 The scoring process for departmental review of images
The 12 components that make a good NT or CRL image are shown in tables 4 and 5 below.
- each image is rated as either ‘good’, ‘acceptance’ or ‘poor’ depending on the score obtained as shown in Table 3
- least image to be considered good or acceptable at least 9 out of the 12 components must be present (75%). In categories of more than one component, there should be no more than 2 components in each section absent
- examples of scored NT images are shown in Diagram 3 and of scored CRL images in Diagram 4

Table 5 - Scoring images

<table>
<thead>
<tr>
<th>Number of components present</th>
<th>Overall Score</th>
</tr>
</thead>
<tbody>
<tr>
<td>All 12 present</td>
<td>GOOD</td>
</tr>
<tr>
<td>9 – 11 present (no more than 2 absent in a section)</td>
<td>ACCEPTABLE</td>
</tr>
<tr>
<td>9 - 11 present (3 or more absent in a section) or 8 or fewer present</td>
<td>POOR</td>
</tr>
</tbody>
</table>

Suggested management following image review
- when all images score either ‘good’ or ‘acceptable’ this demonstrates evidence of good clinical practice
- when any one image scores ‘poor’ it is recommended that a further three paired images are reviewed

If a practitioner continues to score ‘poor’ when these images are reviewed, it is recommended that the ultrasound practitioner has an individualised training plan to support improvements to their imaging and measurement techniques.

Table 4 details the NT and CRL image components that should be analysed and scored using the following image guidance tool.
Table 6 - Image guidance tool for NT

<table>
<thead>
<tr>
<th>Sections</th>
<th>Twelve Components to assess the NT image appearance</th>
</tr>
</thead>
</table>
| Midline section| 1. Horizontal sagittal section of the fetus extending from crown to include at least the upper aspect of the heart*  
2. Head in line with the body with the nuchal translucency visible along the length of the neck  
3. Echogenic tip of the nose  
4. Rectangular shape of the palate  
5. Translucent diencephalon  
6. Frontal process of the maxilla should not be visible (see Diagram 1) |
| Position       | 7. Pocket of fluid, at least equivalent in size to the width of the palate, should be visible between the fetal chin and chest  
8. Angle of the palate relative to the horizontal should be between 30° and 60°  
9. Nasal tip should be level with, or above, the anterior chest wall |
| Magnification  | 10. The section should fill over 60% of the screen |
| Calliper       | 11. Callipers should be placed on the upper and lower skin line (see Diagram 2)  
12. Widest part of the NT should be measured |

*Note the NT and CRL image guidance tool developed with the assumption that the fetus is supine. The image components can still be applied when the fetus is prone, although it may not be possible to score component 3 (echogenic tip of nose). Therefore when the fetus is prone an image score of ‘good’ may not be achievable.

Diagram 1 Images to show absence and presence of frontal process of maxilla

Absence of frontal process of maxilla
Component 6 = ✓

Presence of frontal process of maxilla
Component 6 = X

Diagram 2 Where to place callipers for the NT measurement

Measurement should be taken with the inner border of the horizontal of the callipers placed ON the line that defines the NT thickness. The crossbar of the calliper should be such that it is hardly visible as it emerges with the white line of the border. It should not be visible in the nuchal fluid.

Diagram 3 Examples of scoring NT images

Image 1 Good
### Image 2 Acceptable

<table>
<thead>
<tr>
<th>Midline section</th>
<th>Position</th>
<th>Mag</th>
<th>Callipers</th>
<th>Overall</th>
</tr>
</thead>
<tbody>
<tr>
<td>1 2 3 4 5 6 7 8 9 10 11 12</td>
<td>✓ ✓ ✓ ✓ x ✓ ✓ ✓ ✓ ✓ ✓</td>
<td>✓ ✓ ✓ ✓</td>
<td>✓ ✓ ✓ ✓ ✓</td>
<td></td>
</tr>
</tbody>
</table>

11/12 components present

6) Frontal process of the maxilla is present

### Image 3 Poor

<table>
<thead>
<tr>
<th>Midline section</th>
<th>Position</th>
<th>Mag</th>
<th>Callipers</th>
<th>Overall</th>
</tr>
</thead>
<tbody>
<tr>
<td>1 2 3 4 5 6 7 8 9 10 11 12</td>
<td>✓ ✓ ✓ ✓ ✓ x x ✓ ✓ x ✓ x</td>
<td>✓</td>
<td>✓ x x</td>
<td></td>
</tr>
</tbody>
</table>

7/12 components present

6) Frontal process of the maxilla is present
7) No pocket of fluid under the chin
9) Nasal tip below anterior chest wall
11) Callipers are not correctly placed on the skin lines
12) Widest part of the NT not measured

Poor
## Table 7 - Image guidance tool for the CRL

<table>
<thead>
<tr>
<th>Sections</th>
<th>Twelve Components to assess the CRL image appearance</th>
</tr>
</thead>
</table>
| Midline section  | 1. Sagittal section of the fetus with the head in line with the full length of the body  
|                  | 2. Echogenic tip of the nose                        
|                  | 3. Rectangular shape of the palate                  
|                  | 4. Translucent diencephalon                         
|                  | 5. CRL axis should be between 0° and 30° to the horizontal  
|                  | 6. Clearly defined crown and rump                    |
| Position         | 7. Pocket of fluid, at least equivalent in size to the width of the palate, should be visible between the fetal chin and chest  
|                  | 8. Fetal palate angle should be 30° to 60° relative to the horizontal  
|                  | 9. Nasal tip should be level or above the anterior abdominal wall  |
| Magnification    | 10. Entire CRL section should fill over 60% of the screen |
| Calliper placement | 11. Correct calliper placement on outer borders of crown and rump  
|                  | 12. Longest measurement of the fetus taken           |

## Diagram 4 Examples of scoring CRL images

**Image 4 Good**

<table>
<thead>
<tr>
<th>Midline section</th>
<th>Position</th>
<th>Mag</th>
<th>Callipers</th>
<th>Overall</th>
</tr>
</thead>
<tbody>
<tr>
<td>1</td>
<td>2</td>
<td>3</td>
<td>4</td>
<td>5</td>
</tr>
<tr>
<td>✓</td>
<td>✓</td>
<td>✓</td>
<td>✓</td>
<td>✓</td>
</tr>
<tr>
<td>6</td>
<td></td>
<td></td>
<td></td>
<td></td>
</tr>
<tr>
<td>7</td>
<td>8</td>
<td>9</td>
<td></td>
<td></td>
</tr>
<tr>
<td>✓</td>
<td>✓</td>
<td>✓</td>
<td>✓</td>
<td>✓</td>
</tr>
<tr>
<td>10</td>
<td>11</td>
<td>12</td>
<td></td>
<td></td>
</tr>
</tbody>
</table>

12/12 components present  

<p>| | | | | | | | |</p>
<table>
<thead>
<tr>
<th></th>
<th></th>
<th></th>
<th></th>
<th></th>
<th></th>
<th></th>
<th></th>
</tr>
</thead>
<tbody>
<tr>
<td></td>
<td>1</td>
<td>2</td>
<td>3</td>
<td>4</td>
<td>5</td>
<td>6</td>
<td>7</td>
</tr>
<tr>
<td>✓</td>
<td>✓</td>
<td>✓</td>
<td>✓</td>
<td>✓</td>
<td>✓</td>
<td>✓</td>
<td>✓</td>
</tr>
</tbody>
</table>

**Good**
Departmental review of images

**Image 5 Acceptable**

<table>
<thead>
<tr>
<th>Midline section</th>
<th>Position</th>
<th>Mag</th>
<th>Callipers</th>
<th>Overall</th>
</tr>
</thead>
<tbody>
<tr>
<td>1 2 3 4 5 6 7 8 9 10 11 12</td>
<td>✓ ✓ ✓ x ✓ ✓ ✓ ✓ ✓ ✓ ✓ ✓</td>
<td>✓ ✓ ✓ ✓</td>
<td>✓ ✓ ✓ ✓</td>
<td>✓ ✓ ✓ ✓</td>
</tr>
</tbody>
</table>

11/12 components present

- **Diencephalon absent**

**Image 6 Poor**

<table>
<thead>
<tr>
<th>Midline section</th>
<th>Position</th>
<th>Mag</th>
<th>Callipers</th>
<th>Overall</th>
</tr>
</thead>
<tbody>
<tr>
<td>1 2 3 4 5 6 7 8 9 10 11 12</td>
<td>x ✓ ✓ ✓ ✓ x ✓ ✓ ✓ ✓</td>
<td>✓ ✓ ✓ ✓</td>
<td>✓ ✓ ✓ ✓</td>
<td>x x</td>
</tr>
</tbody>
</table>

8/12 components present

- 1) the full length of the body is not present
- 6) the rump is not clearly defined
- 11) callipers are not correctly placed on the rump
- 12) the longest measurement has not been taken

Withdrawn 17 August 2021
9 DQASS

The role of the screening support sonographer (SSS) is to:
- inform DQASS and screening laboratory of new staff members
- inform DQASS and screening laboratory when a member of staff leaves the Trust
- ascertain from sonographers if they work at other sites and inform DQASS
- monitor throughput for each practitioner
- liaise with laboratory before submission to ensure all practitioner DQASS identity codes are correct and all information is up to date
- receive 6 monthly DQASS report and check for accuracy
- feedback to DQASS any omissions or errors so an updated report can be issued
- feedback DQASS reports to individual sonographers
- develop any red flag action plans with practitioner concerned
- document and organise any support/training required
- maintain departmental log of any practitioners who have combined cycle reports for throughput (for internal information only)
- inform agency sonographers that they are responsible and not DQASS for providing their agency with their DQASS report if it is required

DQASS is a service commissioned by Public health England to support the NHS Fetal Anomaly Screening Programme.

9.1 Aims of DQASS

The main aim of DQASS is to monitor and support the quality and effectiveness of prenatal screening in England. DQASS provides feedback and support to laboratories, sonographers and to the FASP programme.

The analyses provided by DQASS are used to improve the performance of the screening through feedback on all aspects of the test to laboratories, ultrasound departments and commercial suppliers.

DQASS works on a rolling audit of screening test data on a six monthly cycle. The statistical analysis monitors the screening process at various levels; from the overall standardised screen positive rate at the top level to specific adjustments for ethnicity, smoking and other factors applied to individual biomarkers. Through meta-analyses DQASS provides information on effects of factors such as smoking that can be used to improve screening performance.

9.2 Information DQASS needs from laboratories

A designated person in each laboratory should provide data for a 6-month period in Excel format with anonymised individual patient data contained in separate rows. Each column should correspond to a specific data field. The first row should contain the variable label. For the combined test, each row should correspond to a fetus. For the quadruple test, each row should correspond to a pregnancy.

The ultrasound information required is listed below. Detailed information on the demographic and biochemical information can be found in the Laboratory Handbook at: fetalanomaly.screening.nhs.uk/publications

9.2.1 Ultrasound Scan
- scan date
- CRL mm (One decimal place)
- HC mm (One decimal place)
- NT mm (One decimal place)
- DQASS Identity code of sonographer and USS department

The laboratory should liaise with the screening support sonographer (SSS) to ensure that the DQASS ID codes for the sonographers are up to date and that the codes can be matched to an ultrasound department to enable feedback to be given.

9.3 DQASS reports

DQASS undertakes a range of statistical analysis on the data provided and produces reports summarising activity and performance.

Laboratories receive detailed information on serum analyte performance and a summary ultrasound report of the departments they support.

Ultrasound practitioners receive information on their paired NT and CRL distributions in relation to the FMF reference curve and a summary laboratory report will be sent to the SSS.

More information is available at fetalanomaly.screening.nhs.uk/dqass

9.4 Contacting DQASS

- Only the SSS should contact DQASS
- Individual practitioners should not contact DQASS directly
- Contact via email using DQASS@plymouth.ac.uk
- DQASS should not be contacted to ask what date or time reports will be sent
Information required when contacting DQASS via email

Inform of a new staff member
- practitioner’s name
- hospital Unit
- date practitioner started working at the hospital unit
- is this the practitioner’s primary place of work? If ‘No’ where is this sonographer primarily based?
- previous place of work
- provide their unique DQASS identity code matched to an ultrasound department

Request a trainee DQASS identity code
- practitioner’s name
- hospital Unit
- state that they require a trainee DQASS identity code

Sending 25 paired measurements for assessment
- practitioner’s Name
- practitioner’s DQASS identity code matched to an ultrasound department
- hospital Unit
- diagnostic plot

9.5 Completing blood test forms

Ultrasound practitioners are responsible for ensuring the following information is included on the blood test form.
- unique DQASS identity code matched to an ultrasound department
- hospital name
- CRL/HC
- NT measurement
- gestational age
- date of ultrasound scan
- number of fetuses and chorionicity

FASP recommends that practitioners check their NT and CRL distributions at least once within the six-monthly DQASS QA cycle by performing a ‘self-assessment’. This acts as either reassurance or a very helpful early warning sign by increasing awareness of their own performance and allowing them to take corrective action, if necessary, to improve their measurement technique.

Some software IT systems, allow practitioners to check their own distributions. For local organisations that do not have these IT systems, the simple Excel spreadsheet devised by DQASS entitled NT diagnostic plot should be used to check individual distributions.

fetalanomaly.screening.nhs.uk/ssresources

Table 8 - DQASS reports

<table>
<thead>
<tr>
<th>Report</th>
<th>Recipient</th>
<th>Information included</th>
</tr>
</thead>
<tbody>
<tr>
<td>Individual practitioner report</td>
<td>Practitioner via SSS</td>
<td>Practitioner’s DQASS identity code matched to an ultrasound department</td>
</tr>
<tr>
<td></td>
<td>FASP (only red flags)</td>
<td>Number of measurements</td>
</tr>
<tr>
<td></td>
<td>National QA team (only red flags)</td>
<td>Flag status</td>
</tr>
<tr>
<td></td>
<td></td>
<td>Bias relative to FMF reference curve</td>
</tr>
<tr>
<td>Ultrasound Department summary report</td>
<td>SSS</td>
<td>Screening laboratory and time period covered by report</td>
</tr>
<tr>
<td></td>
<td>Laboratory</td>
<td>For each practitioner - DQASS identity code, number of scans, median NT,</td>
</tr>
<tr>
<td></td>
<td>FASP</td>
<td>median CRL, median bias and flag status</td>
</tr>
<tr>
<td></td>
<td>National QA team</td>
<td>95% confidence intervals for estimated bias for each practitioner</td>
</tr>
<tr>
<td></td>
<td>Regional QA team</td>
<td>Previous cycle flag status</td>
</tr>
<tr>
<td></td>
<td>SILs via RQAT</td>
<td></td>
</tr>
<tr>
<td>Laboratory summary report</td>
<td>Laboratory</td>
<td>Number of pregnancies covered in the data set and the number with a risk given</td>
</tr>
<tr>
<td></td>
<td>SSS</td>
<td>DQASS modelled screening performance (DR, FPR, SPR)*</td>
</tr>
<tr>
<td></td>
<td>NHS trust chief executives - all</td>
<td>Data collected, ultrasound measurements and algorithm parameters used</td>
</tr>
<tr>
<td></td>
<td>trusts using the laboratory</td>
<td>First trimester marker performance with reference to the NT comparison to</td>
</tr>
<tr>
<td></td>
<td>FASP</td>
<td>the FMF reference curve</td>
</tr>
<tr>
<td></td>
<td>National QA Team</td>
<td>NT MoM diagnostics</td>
</tr>
<tr>
<td></td>
<td>RQAT</td>
<td>Biochemistry estimated median values</td>
</tr>
<tr>
<td></td>
<td>SILs via Regional QA team</td>
<td>DQASS identity code compliance</td>
</tr>
<tr>
<td></td>
<td></td>
<td>Recommendations and actions</td>
</tr>
</tbody>
</table>

* Detection rate = DR     False positive rate = FPR        Screen positive rate = SPR

9.6 Flag status

Flags are assigned to a dataset of NT and CRL measurements. These flags indicate the bias of the dataset which is the extent of the measurement deviation from the Fetal Medicine Foundation (FMF) reference curve. The evidence used to develop the flag status derived from the impact on screening performance, (Kagan et al 2009).

It is important to note that it is the data set that is flagged NOT the individual practitioner.

Bias can usually be improved by developing a thorough understanding of the factors that affect it. Factors include:

1. machine factors (level of sophistication, recent upgrades, servicing, local quality control (QC) arrangements)
2. ambient light levels within the examination room exceeding Lux level 15
3. department workload and the time allocated to perform the scan
4. departments where slave monitors are not available
5. ultrasound practitioner’s eyesight
6. ultrasound practitioners sharing the same DQASS identity codes
7. very low numbers (less than 25) of NT measurements performed in a six-month period
8. practitioner under or over measuring the CRL
9. practitioner under or over measuring the NT to maintain a bias to the FMF reference curve
10. practitioner’s improvements in measurement technique
11. high-risk caseloads
12. demographic factors (e.g. high prevalence of women with raised BMI)
13. automated measurements

The flag system is designed to help the SSS to identify where to focus training efforts. It is important that all factors affecting the acquisition of high quality images are considered when agreeing an action plan to support ultrasound practitioners.

Examples of distribution plots with flags assigned and how to interpret them can be found in this section.

FASP reviewed the bias deviation relative to the FMF reference curve ranges against the programmes quality agenda and assigned the following categories:

Table 9 - Flag category and bias

<table>
<thead>
<tr>
<th>Flag type</th>
<th>Bias</th>
</tr>
</thead>
<tbody>
<tr>
<td>Green flag</td>
<td>Assigned when bias is less than or equal to 0.10mm</td>
</tr>
<tr>
<td>Amber Flag</td>
<td>Assigned when bias is between 0.11mm and 0.40mm</td>
</tr>
<tr>
<td>Red Flag</td>
<td>Assigned when bias is greater than 0.40mm</td>
</tr>
<tr>
<td>Red Flag with 4</td>
<td>Assigned if fewer than 25 paired CRL/NT measurements over 4 cycles</td>
</tr>
<tr>
<td>No Flag</td>
<td>Assigned if a trainee sonographer has fewer than 25 paired NT/CRL measurements</td>
</tr>
</tbody>
</table>

- each individual report demonstrates the NT and CRL measurements relative to the FMF reference curve
- bias describes the number of measurements above and below the FMF reference curve
- the bias is either negative in terms of under-measurement (below the FMF reference curve) or positive which refers to over-measurement (above the FMF reference curve)
- the evidence used to develop the flag status was derived from the impact on screening performance. For positive biases greater than 0.40mm, the standardised screen positive rate (SPR) exceeds 5% and increases the number of pregnancies exposed to the potential risks and anxieties associated with a screen positive result which may lead to invasive diagnostic procedures.
An example of ‘amber flag’ distribution plot (continue screening)

Diagram 6 Amber bias

This report indicates a negative bias of 0.25mm relative to the FMF reference curve and satisfies the criteria for an amber flag.

This means there are more measurements below the curve (156 – 78%) than there are above (44 – 22%).

Example of ‘red flag’ distribution plot (assess the need for supervised practice)

Diagram 7 Red Flag

This report indicates a positive bias of 0.5mm relative to the FMF reference curve; therefore the data set is assigned a red flag.

This means 92% (185) measurements plotted above the curve, with only 8% (15) plotted below. Bias can directly impact on the risk calculation women receive.

This dataset indicates that there will be an increase in detection rate (91%), however, the standardised SPR is unacceptable and potentially could lead to approximately a 5% increase in invasive procedures performed on unaffected pregnancies.
9.7 Managing red flags

A red flag is issued in two cases
1. bias – if individual bias is greater than 0.40mm
2. throughput – if fewer than 25 paired NT/CRL measurements are submitted over four cycles

Both will potentially impact on detection and screen positive rates, therefore the SSS must inform the practitioner promptly and devise an urgent supportive action plan.

The national quality assurance team maintains a national database of all DQASS identity codes assigned a red flag including training and intervention outcomes.

The local organisation is responsible for ensuring the competency of their employees and should review the individual circumstances and training requirements.

Guidance for managing a red flag for bias
- SSS to inform the ultrasound practitioner and manager
- review equipment, environment, working practices, measurement technique, training and CPD within the last 12 months
- FASP recommends that any practitioner with a dataset assigned a red flag where it is established that additional practice support is required should not screen unsupervised until bias distributions are within the acceptable range following reassessment by DQASS and SSS
- SSS to devise a supportive action plan using the documentation provided in Appendix 2. The training plan should be completed within 12 weeks from commencement and it is recommended that this should include a period of supervised practice
- SSS to send a copy of the training plan to the RQAT, who in turn forward to SIL
- local review of images for new paired measurements against the FASP criteria
- SSS to review new bias distribution and if within acceptable range send to DQASS for analysis
- documentation of support, actions and progress to be maintained
- SSS to keep the RQAT and SIL informed of actions, progress and resolution. This may be done through the quarterly programme board

Diagram 8 Flowchart for management of a red flag for bias

The SSS can consider including a range of educational and operational interventions when devising a supportive action plan. Some examples include:
- complete the online resources
- practical sessions with the SSS
- reminder of how the bias can impact on the risk calculation
- a session reviewing previous and current images using the image guidance tool
- ‘buddying’ alongside a colleague to gain confidence
- a review of the working environment, process and equipment

9.8 Throughput (number of scans undertaken per cycle)
- practitioners must make an individual effort to ensure they meet the NHS minimum requirement of 25 paired NT and CRL measurements within each cycle. This is to ensure individuals remain competent and achieve NT measurement distributions within the acceptable range
- if an ultrasound practitioner does not meet the minimum number of measurements in a cycle, then the number of scans required from up to three previous cycles will be amalgamated with the current cycle to reach the minimum 25 required
- a departmental log of reasons why the cycles were combined should be maintained by SSS
- the bias will be calculated and any appropriate action plans should be applied
- if the amalgamated throughput is still less than 25 after combining four cycles then a red flag with a 4 will be issued
the Trust should consider whether a practitioner with a red flag for throughput should continue participation in the NHS screening programme

9.9 Guidance for managing red flag for throughput

- SSS to inform the ultrasound practitioner and manager/clinical director
- discussion as to whether it needs to be put on the Trust’s risk register must take place
- if necessary the SSS may escalate to the superintendent sonographer or head of midwifery
- SSS to devise a supportive action plan using the documentation provided in Appendix 3
- SSS to liaise with the RQAT and SIL for advice and support
- SSS to send action plan to the RQAT who in turn will send it to the SIL
- SSS to keep the RQAT and SIL informed of actions, progress and resolution
- documentation of support, actions and progress to be maintained
- discuss at both the local screening board and the quarterly programme board

9.10 Scenarios

DQASS report received.

<table>
<thead>
<tr>
<th>DQASS identity code</th>
<th>Number of paired measurements</th>
<th>Bias</th>
<th>Flag</th>
</tr>
</thead>
<tbody>
<tr>
<td>9898989</td>
<td>25</td>
<td>0.08</td>
<td>Green</td>
</tr>
<tr>
<td>7676767</td>
<td>25</td>
<td>-0.46</td>
<td>Red</td>
</tr>
<tr>
<td>5454545</td>
<td>16</td>
<td></td>
<td>Red*</td>
</tr>
</tbody>
</table>

Practitioner 9898989 has been on long term sick and has only 8 paired NT/CRL measurements in current cycle.
- DQASS combines those with 17 measurements from previous cycle to get 25
- the bias is assessed and a green flag issued
- practitioner continues to practice as bias acceptable

Practitioner 7676767 has just returned from maternity leave and only has 2 paired NT/CRL measurements in current cycle.
- DQASS combines those from 2 previous cycles to get 25 measurements
- the bias is assessed and a red flag for bias is issued
- SSS to devise red flag action plan for bias

Practitioner 5454545 performs very low number of obstetric scans and only has 2 paired NT/CRL measurements in current cycle.
- DQASS combines all measurements with the 3 previous cycles but the practitioner still has fewer than 25 measurements
- bias cannot be assessed and a red flag with a 4 is issued for throughput
- SSS to devise red flag action plan for throughput

10 Education and Training

10.1 NHS model of training in NT and CRL measurements

There are two components:
1. theory component
2. practical component

10.2 Theory component

- there are two online resources that contain current recommendations and guidance on screening

FASP recommends that any practitioner undertaking a first and/or any ultrasound scan on pregnant women, for the purpose of screening and diagnosis of a related condition should hold, as a minimum, one of the following:
- Certificate/Diploma (as appropriate) in Medical Ultrasound (CMU/DMU) of the College of Radiographers (CoR) with evidence of appropriate continuous professional development (CPD)
- Post Graduate Certificate in Medical Ultrasound (PgCert) approved and validated by a Higher Institute of Education and accredited by the Consortium for Sonographic Education (CASE) or equivalent.
- The qualification should be relevant to obstetric ultrasound practice
- Royal College of Obstetricians and Gynaecologists (RCOG)/Royal College of Radiologists (RCR) Diploma in Obstetric Ultrasound or the Advanced Training Skills Module (ATSM)
- It is recommended that these resources are reviewed as part of continuous professional development to ensure all ultrasound practitioners remain informed of any guidance changes. A reminder will be sent one month in advance to each registered practitioner when it is time to review the modules.

The theoretical modules include:
- Condensed Education Modules for Trisomy 21 (CEMT21). An education module which aims to support health professionals who care for women and their families along the screening pathway (60–90 minutes). To be completed every 24 months
- NT training resource. This resource supports practitioners undertaking the ultrasound component of the combined screening test (60–90 minutes). To be completed every 12 months

The role of the screening support sonographer (SSS) is to:
- inform DQASS of a new practitioner’s details to obtain DQASS identity training code matched to an ultrasound department
- ensure online training is completed and record dates
- review images before adding paired measurements to DQASS
- send 25 paired measurements to DQASS
- ensure ongoing review is all practitioners of online theory training resources and record dates
- both resources must be undertaken prior to starting practical training
- registration is required to access these modules and a certificate of completion is provided
- the SSS has access to audit staff completion of the resources. The certificate of completion does not indicate competency to perform the required measurements but indicates appropriate theory training is complete
10.3 Practical component

This training is overseen by the SSS and it is important that some of the practical training sessions are with the SSS. The minimum practical training requirements are set out in Table 11.

Table 11 - Practical training requirement

<table>
<thead>
<tr>
<th>Number of scans/images/measurements</th>
<th>Action</th>
</tr>
</thead>
<tbody>
<tr>
<td>1-5 scans</td>
<td>Observation</td>
</tr>
<tr>
<td>10-20 scans</td>
<td>Supervised by the SSS</td>
</tr>
<tr>
<td>3-5 images</td>
<td>Independently performed and reviewed with SSS as acceptable or good</td>
</tr>
<tr>
<td>25 paired measurements</td>
<td>SSS to send diagnostic plot to DQASS *</td>
</tr>
</tbody>
</table>

* A diagnostic plot self-assessment tool is provided for practitioners to enter their 25 paired measurements. This must be used when the SSS sends the data to DQASS and can be found at [fetalanomaly.screening.nhs.uk/SSSresources](http://fetalanomaly.screening.nhs.uk/SSSresources).

To commence practical training a unique identity code from DQASS is required.

Ultrasound practitioners in some departments require a Fetal Medicine Foundation (FMF) code to access risk assessment software locally. Where this is the case, DQASS will use the FMF identity code for the practitioner but it is important to note that this only applies to FMF codes issued in England. Ultrasound practitioners with an FMF identity code from outside England will require a DQASS training code. The SSS plays a pivotal role in communicating with DQASS in these circumstances.

DQASS issues the unique DQASS identity code matched to an ultrasound department to the SSS with the suffix “T” to indicate a practitioner in training.

It is acknowledged that the level of support required may also vary.

Recommendations
- if new staff member, SSS to email DQASS and screening laboratory with details
- practical support should be decided on an individual basis with the SSS
- SSS to document any decisions on training and support that may be required
- both online theoretical resources are reviewed
- SSS review images as satisfactory
- 25 paired measurements sent to DQASS for assessment
- SSS confirm practitioner is approved to continue screening
11 Quality Improvement and Assurance

Table 12 - Summary of training requirements

<table>
<thead>
<tr>
<th>Staff member</th>
<th>Training Requirement</th>
</tr>
</thead>
</table>
| **Experienced practitioner returning to practice or new staff member** | • Online NHS NT resource  
• Online CEM T21 course  
• Period of supported practice is required  
• Images reviewed with SSS  
• SSS to send 25 paired measurements to DQASS  
• SSS confirm may continue screening |
| **Trainee** | • DQASS provide identity training code linked to a department  
• Online NHS NT resource  
• Online CEM T21 course  
• Visit screening laboratory  
• Supported practical training  
• Images reviewed with SSS  
• SSS to send 25 paired measurements to DQASS  
• SSS confirm may continue screening  
• If student – continued supervised practice until qualified |

Screening Matters

Screening Matters is the newsletter of the UK NSC. It is aimed at everyone involved in screening - policy makers, commissioners, providers and wider public health professionals. It covers evidence and policy development, training and education, quality assurance and IT and information, as well as providing updates on all the antenatal, newborn and young persons and adult screening programmes in England. It is published three times a year - in February, June and October.

You can register to receive screening matters at [www.screening.nhs.uk/screeningmatters](http://www.screening.nhs.uk/screeningmatters)

11.1 Quality Improvement

Each local programme must have clear arrangements for managing quality and have a systematic approach to quality improvement. Participation in regional quality assurance activity is in addition to routine departmental quality improvement (such as failsafe checks, departmental audit, learning and development) and regular, informal contact with QA teams. It is not intended to preclude local initiatives or more detailed internal scrutiny of professional performance.

A local programme, which has effective departmental QA processes in operation, will be well placed to respond with minimum effort to scheduled QA assessments.

11.2 Quality Assurance (QA)

Each NHS screening programme has a defined set of standards that providers have to meet to ensure that local programmes are safe and effective. Quality assurance (QA) is the process of checking that these standards are met and encouraging continuous improvement and includes:

- advice on the development of national quality standards
- monitoring of how services meet (or fail to meet) standards
- providing expert screening advice for incident management
- facilitating quality review of services, including peer advice
- support on a day-to-day basis, those involved in commissioning or providing screening services.

QA covers the entire screening pathway; from identifying who is eligible to be invited to screening, through to referral and treatment where required/appropriate.

The aim of QA in NHS antenatal and newborn screening programmes is the maintenance of minimum standards and the continuous improvement in the performance of all aspects of screening to ensure that all women and their babies have access to high quality screening wherever they live. QA is essential in order to minimise harm and maximise benefits of screening.

Formal QA visits to a local screening programme provide the forum for a peer review of the whole multidisciplinary screening pathway, and an assessment of the effectiveness of team working within the local screening programme and associated referral sites.

- regional teams advise providers and commissioners about reducing risks in local screening programmes
- they assess the robustness of local arrangements through audit, as part of peer review and in the investigation of any incidents as they occur
- they act as a conduit for information and dialogue at national, regional and local levels, additionally sharing good practice
- participation in a formal process of QA is the responsibility of each local screening programme
- the performance of the local programmes is monitored in a variety of ways such as review of statistics, regional meetings or informal...
11.3 Key performance indicators (KPIs)

Key performance indicators (KPIs) for the NHS screening programmes were introduced to provide a way of measuring how well the screening programmes are doing in important areas. They contribute to the quality assurances of screening programmes but are not, in themselves, sufficient to quality assure or performance manage screening services. They help local screening services to identify potential problems so they can be put right and have led to changes in practice and implementation of measures to prevent errors occurring in the screening pathway.

More information on KPIs can be found at www.screening.nhs.uk/kpi

11.4 Screening safety incidents

A screening safety incident is any unintended or unexpected incident(s) that could have or did lead to harm to one or more persons who are eligible for NHS screening, or to staff working in the screening programme.

A screening safety incident can affect populations as well as individuals. It is an actual or possible failure in the screening pathway and at the interface between screening and the next stage of care. Although the level of risk to an individual in an incident may be low, because of the large numbers of people offered screening, this may equate to a high corporate risk. It is important to ensure that there is a proportionate response based on an accurate investigation and assessment of the risk of harm. Due to the public interest in screening, the likelihood of adverse media coverage with resulting public concern is high even if no harm occurs.

More information about managing screening safety incidents is available at:
- www.screening.nhs.uk/incidents
- cpd.screening.nhs.uk/incident-resource

Lessons to be learnt from screening incidents can be found at:
- www.screening.nhs.uk/si-learning

12 Information for the public

Screening Tests for You and Your Baby (STFYAYB) is the recommended information booklet covering both antenatal and newborn screening. Each screening programme is described in a standard format. This makes it easier for the public to compare the various tests and, crucially, to understand that some decisions are more complex than others.

A copy of STFYAYB can be accessed at www.screening.nhs.uk/annbpublications

Acknowledgments

The Fetal Anomaly Screening Programme expresses thanks to members of the Laboratory & Ultrasound Group who contributed to the production of this handbook.
Glossary

Amniocentesis
An invasive procedure undertaken from about 15 completed weeks (15+) onwards to obtain a sample of amniotic fluid (liquor) surrounding the fetus. Using an aseptic technique whilst under continuous ultrasound guidance, a sterile needle is passed through the mother’s abdomen, uterus and amniotic sac. A sample of amniotic fluid is aspirated with a syringe and sent for analysis to test for a range of chromosomal and inherited disorders. Out of 100 women who have this test from 15 weeks it is likely that one will miscarry as a direct consequence of the procedure.

Amniotic fluid
Also known as ‘liquor’, this is the fluid surrounding the fetus during pregnancy. It contains substances and cells from the fetus, which can be removed by amniocentesis and examined.

Anomaly
An aberration or change often used related to a gene or physical structure that may or may not result in a disease or condition.

Biochemical markers
Analytes (commonly referred to as markers) measured by the laboratory that are used to calculate the likelihood of a pregnancy being affected by a condition or syndrome.

Chorionic Villus Sampling (CVS)
An abdominal or cervical procedure performed under continuous ultrasound guidance after 10 completed weeks in pregnancy to obtain a sample of placental tissue for chromosomal or genetic analysis. The range of chromosomal and genetic conditions that can be detected is similar to those for amniocentesis. For every 100 women who have this test from 11 weeks onwards it is likely that one will miscarry.

Combined test
Between 11 weeks and 2 days and 14 weeks and 1 day of pregnancy, a combination of the nuchal scan measurement and a blood sample from the mother which measures the concentration of pregnancy associated plasma protein-A (PAPP-A), and free beta human chorionic gonadotrophin (Free beta hCG). Together with the mother’s age and the gestation of the pregnancy, these are used to estimate the chances that the fetus is affected with Down’s syndrome.

Crown rump length (CRL)
Ultrasound measurement between the top of the head (crown) to the bottom of the buttocks (rump)

Detection rate
The proportion of affected individuals with a positive screening result.

Diagnostic test
Refers to the process involved in obtaining a definite diagnosis. For example the diagnostic test on an amniocentesis sample (invasive procedure) is the full karyotype or QF-PCR.

Down’s Syndrome (trisomy 21)
A disorder caused by the presence of an extra copy (three instead of two) of chromosome 21. It affects all population groups and is distinguished by a number of features occurring together, including low muscle tone, a flattened face with eyes slanting upward, small ears and an unusually wide neck and a deep crease across the palm of the hand. Some may have heart problems or visual problems that may develop into Alzheimer’s disease. Although people with Down’s syndrome have learning difficulties, these vary in severity.

Edwards’ Syndrome (trisomy 18)
A syndrome caused by the presence of an extra copy (three instead of two) of chromosome 18. The combination of features present in babies affected with trisomy 18 can lead to many different problems including growth deficiency, feeding and breathing difficulties, developmental delay, learning difficulties, undescended testes in males, kidney malformations, heart defects. They may also have malformations in the bones.

Survival of infants with trisomy 18 depends on how severely they are affected. Most do not survive the first year of life.

Fetal anomaly
Structural abnormalities with how the fetus has developed.

Fetal anomaly ultrasound scan
A screening test offered to pregnant women to monitor the growth and development of the fetus before birth by producing a real-time visual image. Scans before 10 weeks are not useful for dating and assessing the viability of the pregnancy and are unable to detect some major malformations. Detailed scanning at 18 weeks, 8 days to 20 weeks, 6 days should show up most malformations as well as some minor ones.

Gestational age
The duration of an ongoing or completed pregnancy, measured from the first day of the last menstrual period (usually about two weeks longer than that measured from conception). Gestational age is usually measured in weeks and days.

Invasive diagnostic procedure
A method used to obtain a sample used to aid diagnosis, for example, amniocentesis or chorionic villus sampling.

Marker
An identifiable physical location on a chromosome whose inheritance can be monitored. Markers can be expressed regions of DNA (genes) or some segment of DNA with no known coding function but whose pattern of inheritance can be determined.

Nuchal scan (Nuchal translucency scan NT)
Between 11 weeks and 2 days and 14 weeks and 1 day of pregnancy the thickness of fluid in the tissue space within the nape of the fetal neck, the nuchal translucency can be measured. An increased amount of fluid may indicate that the fetus has Down’s syndrome, structural or genetic anomaly. By combining the mother’s age and the gestation of the pregnancy with information from the scan an individual statistical chance of an anomaly can be given for that particular pregnancy. If the chance is one in 150 or higher a diagnostic test, such as CVS, will be offered.

Patau’s Syndrome (trisomy 13)
A disorder caused by the presence of an extra copy (three instead of two) of chromosome 13. The disorder is characterised by low birth weight, cleft lip or palate, defects of the heart, eye structure, spine, scalp and abdomen, abnormal genitalia, low set ears, abnormal palm pattern, extra digits and overlapping of fingers over thumb. Between 80 per cent and 90 per cent of babies do not survive infancy and those that do survive have learning disabilities.

Prenatal
Relating to the period before birth

Quadruple test
Second trimester test to calculate the risk of Down’s syndrome, usually based on the measurement of AFP, uE3, free b-hCG (or total hCG), and inhibin-A together with the woman’s age.

Quality assurance (QA)
A system for monitoring and maintaining high standards in every aspect of a screening programme.

Risk
Risk is usually taken to mean the chance of an event happening. It can be be expressed in a number of ways, see diagrams in the UK NSC Resource Cards for Midwives Nos 3 and 5.

Risk cut-off
Determines those women who are in the ‘higher risk’ group and considered ‘screen positive’.

Screen positive rate (SPR)
The number of women who receive a higher risk result.

Screening
Testing people who do not have or have not recognised the signs or symptoms of the condition being tested for, either with the aim of reducing risk of an adverse outcome, or with the aim of giving information about risk.
Screening pathway
The whole system of activities needed to deliver high quality screening. It ranges from identifying and informing those to be offered screening through to the treatment and follow up of those found to have abnormality, and support for those who develop disease despite screening.

Screening programme
The whole system of activities needed to deliver high quality screening. It ranges from identifying and informing those to be offered screening through to the treatment and follow up of those found to have abnormality, and support for those who develop disease despite screening.

Screening safety incident
An unintended or unexpected incident(s) that could have or did lead to harm to one or more persons who are eligible for NHS screening; or to staff working in the screening programme.

Screening test
A test or inquiry used on people who do not have or have not recognised the signs or symptoms of the condition being tested for. It divides people into low and higher risk groups.

Syndrome
Combination of symptoms and signs grouped together to form a disorder.

Throughput
Number of samples undertaken per cycle.

Trisomy
Three copies of a particular chromosome rather than the usual pair.

Ultrasound scan
A ultrasound scan is a safe and painless test that uses sound waves to make images. It is like radar.

Tables, Diagrams and Images

| Table 1 | National standards for screening tests | Page 9 |
| Table 2 | Maternal age and chance/probability of having a pregnancy affected by Down’s syndrome | Page 10 |
| Table 3 | Recommended criteria for measurement of NT for the purposes of combined screening | Page 14 |
| Table 4 | Recommended criteria for measurement of CRL for purposes of pregnancy dating and combined screening | Page 15 |
| Table 5 | Scoring images for departmental review of images | Page 17 |
| Table 6 | Image guidance tool for NT | Page 18 |
| Table 7 | Image guidance tool for the CRL | Page 22 |
| Table 8 | DQASS reports | Page 29 |
| Table 9 | Flag category and bias | Page 30 |
| Table 10 | Scenarios | Page 36 |
| Table 11 | Practical training requirement | Page 38 |
| Table 12 | Summary of training requirements | Page 40 |

| Diagram 1 | Images to show absence and presence of frontal process of maxilla | Page 18 |
| Diagram 2 | Where to place callipers for the NT measurement | Page 19 |
| Diagram 3 | Examples of scoring NT images | Page 19 |
| Diagram 4 | Examples of scoring CRL images | Page 23 |
| Diagram 5 | Example of ‘green flag’ distribution plot | Page 31 |
| Diagram 6 | Example of ‘amber flag’ distribution plot | Page 32 |
| Diagram 7 | Example of ‘red flag’ distribution plot | Page 33 |
| Diagram 8 | Flowchart for management of a red flag for bias | Page 35 |
| Diagram 9 | Progression of training for practitioners new to NT measurement | Page 39 |

| Image 1 | Images to show absence and presence of frontal process of maxilla – Good | Page 19 |
| Image 2 | Images to show absence and presence of frontal process of maxilla – Acceptable | Page 20 |
| Image 3 | Images to show absence and presence of frontal process of maxilla – Poor | Page 21 |
| Image 4 | Examples of scoring CRL images – Good | Page 23 |
| Image 5 | Examples of scoring CRL images – Acceptable | Page 24 |
| Image 6 | Examples of scoring CRL images – Poor | Page 25 |
References


Abbreviations

<table>
<thead>
<tr>
<th>Abbreviation</th>
<th>Description</th>
</tr>
</thead>
<tbody>
<tr>
<td>AFP</td>
<td>Alpha fetoprotein</td>
</tr>
<tr>
<td>BPD</td>
<td>Biparietal Diameter</td>
</tr>
<tr>
<td>CEMT21</td>
<td>Condensed Education Modules for Trisomy 21</td>
</tr>
<tr>
<td>CPD</td>
<td>Continuous professional development</td>
</tr>
<tr>
<td>CRL</td>
<td>Crown Rump Length</td>
</tr>
<tr>
<td>DQASS</td>
<td>Down’s syndrome screening Quality Assurance Support Service</td>
</tr>
<tr>
<td>DR</td>
<td>Detection rate</td>
</tr>
<tr>
<td>FASP</td>
<td>Fetal Anomaly Screening Programme</td>
</tr>
<tr>
<td>FMF</td>
<td>Fetal Medicine Foundation</td>
</tr>
<tr>
<td>FPR</td>
<td>False Positive Rate</td>
</tr>
<tr>
<td>HC</td>
<td>Head Circumference</td>
</tr>
<tr>
<td>HCG</td>
<td>Human chorionic gonadotrophin</td>
</tr>
<tr>
<td>KPI</td>
<td>Key Performance Indicator</td>
</tr>
<tr>
<td>MoM</td>
<td>Median multiple of the median</td>
</tr>
<tr>
<td>NT</td>
<td>Nuchal Translucency measurement</td>
</tr>
<tr>
<td>OFD</td>
<td>Occipital-frontal diameter</td>
</tr>
<tr>
<td>PAPP-A</td>
<td>Pregnancy associated plasma protein – A</td>
</tr>
<tr>
<td>PHE</td>
<td>Public Health England</td>
</tr>
<tr>
<td>QA</td>
<td>Quality Assurance</td>
</tr>
<tr>
<td>RQAT</td>
<td>Regional Quality Assurance Team</td>
</tr>
<tr>
<td>SIL</td>
<td>Screening and Immunisation Lead</td>
</tr>
<tr>
<td>SIT</td>
<td>Screening and Immunisation Team</td>
</tr>
<tr>
<td>SPR</td>
<td>Screen Positive Rate</td>
</tr>
<tr>
<td>SSS</td>
<td>Screening Support Sonographer</td>
</tr>
<tr>
<td>STFYAYB</td>
<td>Screening Tests for You and Your Baby</td>
</tr>
<tr>
<td>T</td>
<td>Trisomy</td>
</tr>
<tr>
<td>uE3</td>
<td>Unconjugated oestriol</td>
</tr>
<tr>
<td>UK NSC</td>
<td>United Kingdom National Screening Committee</td>
</tr>
</tbody>
</table>
## Appendix 1. Score sheets

### NT score sheet

<table>
<thead>
<tr>
<th>Score</th>
<th>Description</th>
</tr>
</thead>
<tbody>
<tr>
<td>1</td>
<td>Horizontal mid-sagittal section of head in line with body, visible skin line</td>
</tr>
<tr>
<td>2</td>
<td>Echogenic tip of the nose</td>
</tr>
<tr>
<td>3</td>
<td>Rectangular shape of the palate</td>
</tr>
<tr>
<td>4</td>
<td>Translucent diencephalon</td>
</tr>
<tr>
<td>5</td>
<td>Frontal process of maxilla not visible</td>
</tr>
<tr>
<td>6</td>
<td>Pocket of fluid under chin visible</td>
</tr>
<tr>
<td>7</td>
<td>Nasal tip level or above chest wall</td>
</tr>
<tr>
<td>8</td>
<td>Palate angle 30 - 60°</td>
</tr>
<tr>
<td>9</td>
<td>Fills over 60% of the screen</td>
</tr>
<tr>
<td>10</td>
<td>Callipers on upper and lower skin line</td>
</tr>
<tr>
<td>11</td>
<td>Measure widest part of NT</td>
</tr>
<tr>
<td>12</td>
<td>Outcome</td>
</tr>
<tr>
<td></td>
<td>Comments</td>
</tr>
</tbody>
</table>

- **Patient ID**
- **Date of review**
- **Assessor**
Appendix 2. Red flag action plan (bias)

Suggested action plan for practitioners assigned a red flag for bias

<table>
<thead>
<tr>
<th>Action Description</th>
<th>Date Completed</th>
<th>Comments</th>
</tr>
</thead>
<tbody>
<tr>
<td>Practitioner informed by SSS</td>
<td></td>
<td></td>
</tr>
<tr>
<td>Supervised screening commenced</td>
<td></td>
<td></td>
</tr>
<tr>
<td>Manager and local screening board informed</td>
<td></td>
<td></td>
</tr>
<tr>
<td>Review equipment, environment, working practices, technique and training needs</td>
<td></td>
<td></td>
</tr>
<tr>
<td>SSS to review previous paired images with practitioner</td>
<td></td>
<td></td>
</tr>
<tr>
<td>SSS to liaise with Regional QA team</td>
<td></td>
<td></td>
</tr>
<tr>
<td>Confirm action plan in place with Regional QA team within 2 weeks of DQASS report being received. (Regional QA team to inform SIL team).</td>
<td></td>
<td></td>
</tr>
<tr>
<td>Review online training resources</td>
<td></td>
<td></td>
</tr>
<tr>
<td>Supervised training sessions with SSS</td>
<td></td>
<td></td>
</tr>
<tr>
<td>SSS to review new images to confirm acceptable</td>
<td></td>
<td></td>
</tr>
<tr>
<td>SSS to send 25 paired measurements to DQASS</td>
<td></td>
<td></td>
</tr>
<tr>
<td>DQASS confirm new measurements within acceptable range</td>
<td></td>
<td></td>
</tr>
<tr>
<td>SSS confirms practitioner may resume independent practice</td>
<td></td>
<td></td>
</tr>
<tr>
<td>Review of outcome within 12 weeks and update sent by SSS to regional QA team</td>
<td></td>
<td></td>
</tr>
</tbody>
</table>

FASP recommends that an individual training plan be negotiated between SSS and practitioner.
Appendix 3. Red flag action plan (throughput)

Suggested action plan for practitioners assigned a red flag for throughput.

<table>
<thead>
<tr>
<th>Practitioner ID number</th>
<th>Audit cycle number</th>
<th>Name of SSS</th>
<th>Name of local organisation/NHS trust</th>
<th>Date</th>
</tr>
</thead>
<tbody>
<tr>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
</tr>
</tbody>
</table>

FASP recommends that an individual training plan be negotiated between SSS and practitioner.

<table>
<thead>
<tr>
<th>Action</th>
<th>Date Completed</th>
<th>Comments</th>
</tr>
</thead>
<tbody>
<tr>
<td>Practitioner informed by SSS</td>
<td></td>
<td></td>
</tr>
<tr>
<td>Unsupervised screening ceases</td>
<td></td>
<td></td>
</tr>
<tr>
<td>Manager and local ANNBSP board informed</td>
<td></td>
<td></td>
</tr>
<tr>
<td>Review working practices</td>
<td></td>
<td></td>
</tr>
<tr>
<td>SSS to liaise with Regional QA team</td>
<td></td>
<td></td>
</tr>
<tr>
<td>Confirm action plan in place with Regional QA team within 2 weeks of DQASS report being received. (Regional QA team to inform SIL team)</td>
<td></td>
<td></td>
</tr>
<tr>
<td>DQASS reassess bias and throughput as acceptable</td>
<td></td>
<td></td>
</tr>
<tr>
<td>SSS confirms practitioner may resume independent practice</td>
<td></td>
<td></td>
</tr>
<tr>
<td>Review of outcome within 12 weeks and update sent by SSS to regional QA</td>
<td></td>
<td></td>
</tr>
</tbody>
</table>

Appendix 4. Training logbook for new practitioners

<table>
<thead>
<tr>
<th>Name of ultrasound practitioner</th>
<th>DQASS identity code</th>
<th>Name of SSS</th>
<th>Name of organisation/NHS trust</th>
</tr>
</thead>
<tbody>
<tr>
<td></td>
<td></td>
<td></td>
<td></td>
</tr>
</tbody>
</table>

<table>
<thead>
<tr>
<th>ITEM</th>
<th>Date completed</th>
<th>Comments</th>
</tr>
</thead>
<tbody>
<tr>
<td>Condensed education module for T21 (CEMT21) Essential</td>
<td></td>
<td></td>
</tr>
<tr>
<td>NT training resource Essential</td>
<td></td>
<td></td>
</tr>
<tr>
<td>Training number requested from DQASS</td>
<td></td>
<td></td>
</tr>
<tr>
<td>Log-book of supervised scans completed</td>
<td></td>
<td></td>
</tr>
<tr>
<td>Log book of 25 independent scans completed</td>
<td></td>
<td></td>
</tr>
<tr>
<td>Images reviewed and scored as good or acceptable with SSS</td>
<td></td>
<td></td>
</tr>
<tr>
<td>25 paired measurements submitted to DQASS</td>
<td></td>
<td></td>
</tr>
<tr>
<td>SSS confirms competent to scan independently</td>
<td></td>
<td></td>
</tr>
</tbody>
</table>

Signed declaration

The above named ultrasound practitioner has successfully completed all the training requirements and is therefore competent to undertake the ultrasound aspect of the NHS T21 combined screening programme.

Signature of SSS

Date.
Appendix 5. Return to practice logbook

<table>
<thead>
<tr>
<th>DQASS identity code</th>
<th>Name of SSS</th>
<th>Name of organisation/NHS trust</th>
</tr>
</thead>
<tbody>
<tr>
<td>ITEM</td>
<td>Date completed</td>
<td>Comments</td>
</tr>
<tr>
<td>Condensed education module for T21 (CEMT21) Essential</td>
<td></td>
<td></td>
</tr>
<tr>
<td>NT training resource Essential</td>
<td></td>
<td></td>
</tr>
<tr>
<td>Supported practice if required</td>
<td></td>
<td></td>
</tr>
<tr>
<td>Satisfactory image review with SSS completed</td>
<td></td>
<td></td>
</tr>
<tr>
<td>25 paired measurements submitted to DQASS</td>
<td></td>
<td></td>
</tr>
<tr>
<td>SSS confirms may continue screening</td>
<td></td>
<td></td>
</tr>
</tbody>
</table>